LymphedemaV1, Pmc, Corpus, bibRecord, 002D01

Five-year follow-up of treatment outcomes in patients with early-stage breast cancer and clinically negative axillary nodes treated with no lymph node dissection or axillary clearance

Identifieur interne : 002D01 ( Pmc/Corpus ); précédent : 002D00; suivant : 002D02

Five-year follow-up of treatment outcomes in patients with early-stage breast cancer and clinically negative axillary nodes treated with no lymph node dissection or axillary clearance

Auteurs : Daigo Yamamoto ; Kanji Tanaka ; Yu Tsubota ; Noriko Sueoka ; Tetsuji Shoji ; Kayoko Kuwana ; A-Hon Kwon

Source :

Breast Cancer : Targets and Therapy [ 1179-1314 ] ; 2012.

RBID : PMC:3846707

Abstract

Background

Sentinel lymph node biopsy has steadily replaced axillary lymph node dissection (ALND) for staging clinically node-negative breast cancer. However, ALND remains standard management of the axilla when a tumor-positive sentinel lymph node is identified.

Methods

We identified 460 patients with breast cancer (clinically T1/T2N0M0) from the database for 1999–2004. Patient age ranged from 26 to 81 (median 50) years. Patients who underwent mastectomy or breast-conserving surgery with or without ALND were compared for regional recurrence, disease-free survival, and overall survival.

Results

Patients with ALND (n = 308) were compared with the no ALND group (n = 152). Five-year overall survival and disease-free survival were not significantly different between the two groups, while there was a significant difference between them for regional recurrence. Of the 152 patients who did not undergo axillary dissection, four developed ipsilateral axillary disease, most of whom were rescued by delayed axillary dissection. Further, the criterion for identifying lymphedema was used, ie, a 2 cm circumferential change at any measured location. As a result, the incidence of lymphedema in the ALND group was 12.7%, while it was not seen in the non ALND group.

Conclusion

There is a possibility that ALND may be omitted for cT1/T2N0M0 breast cancer through a combination of hormone therapy and adjuvant chemotherapy.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846707

DOI: 10.2147/BCTT.S36054
PubMed: 24367200
PubMed Central: 3846707

Links to Exploration step

PMC:3846707

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Five-year follow-up of treatment outcomes in patients with early-stage breast cancer and clinically negative axillary nodes treated with no lymph node dissection or axillary clearance</title>
<author><name sortKey="Yamamoto, Daigo" sort="Yamamoto, Daigo" uniqKey="Yamamoto D" first="Daigo" last="Yamamoto">Daigo Yamamoto</name>
<affiliation><nlm:aff id="af1-bctt-4-125">Department of Surgery, Kansai Medical University, Hirakata, Japan</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Tanaka, Kanji" sort="Tanaka, Kanji" uniqKey="Tanaka K" first="Kanji" last="Tanaka">Kanji Tanaka</name>
<affiliation><nlm:aff id="af2-bctt-4-125">Ribon-Rose Tanaka Kanji Breast Clinic, Japan</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Tsubota, Yu" sort="Tsubota, Yu" uniqKey="Tsubota Y" first="Yu" last="Tsubota">Yu Tsubota</name>
<affiliation><nlm:aff id="af1-bctt-4-125">Department of Surgery, Kansai Medical University, Hirakata, Japan</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Sueoka, Noriko" sort="Sueoka, Noriko" uniqKey="Sueoka N" first="Noriko" last="Sueoka">Noriko Sueoka</name>
<affiliation><nlm:aff id="af1-bctt-4-125">Department of Surgery, Kansai Medical University, Hirakata, Japan</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Shoji, Tetsuji" sort="Shoji, Tetsuji" uniqKey="Shoji T" first="Tetsuji" last="Shoji">Tetsuji Shoji</name>
<affiliation><nlm:aff id="af3-bctt-4-125">Shoji Clinic, Osaka, Japan</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kuwana, Kayoko" sort="Kuwana, Kayoko" uniqKey="Kuwana K" first="Kayoko" last="Kuwana">Kayoko Kuwana</name>
<affiliation><nlm:aff id="af1-bctt-4-125">Department of Surgery, Kansai Medical University, Hirakata, Japan</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kwon, A Hon" sort="Kwon, A Hon" uniqKey="Kwon A" first="A-Hon" last="Kwon">A-Hon Kwon</name>
<affiliation><nlm:aff id="af1-bctt-4-125">Department of Surgery, Kansai Medical University, Hirakata, Japan</nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">24367200</idno>
<idno type="pmc">3846707</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846707</idno>
<idno type="RBID">PMC:3846707</idno>
<idno type="doi">10.2147/BCTT.S36054</idno>
<date when="2012">2012</date>
<idno type="wicri:Area/Pmc/Corpus">002D01</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002D01</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Five-year follow-up of treatment outcomes in patients with early-stage breast cancer and clinically negative axillary nodes treated with no lymph node dissection or axillary clearance</title>
<author><name sortKey="Yamamoto, Daigo" sort="Yamamoto, Daigo" uniqKey="Yamamoto D" first="Daigo" last="Yamamoto">Daigo Yamamoto</name>
<affiliation><nlm:aff id="af1-bctt-4-125">Department of Surgery, Kansai Medical University, Hirakata, Japan</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Tanaka, Kanji" sort="Tanaka, Kanji" uniqKey="Tanaka K" first="Kanji" last="Tanaka">Kanji Tanaka</name>
<affiliation><nlm:aff id="af2-bctt-4-125">Ribon-Rose Tanaka Kanji Breast Clinic, Japan</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Tsubota, Yu" sort="Tsubota, Yu" uniqKey="Tsubota Y" first="Yu" last="Tsubota">Yu Tsubota</name>
<affiliation><nlm:aff id="af1-bctt-4-125">Department of Surgery, Kansai Medical University, Hirakata, Japan</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Sueoka, Noriko" sort="Sueoka, Noriko" uniqKey="Sueoka N" first="Noriko" last="Sueoka">Noriko Sueoka</name>
<affiliation><nlm:aff id="af1-bctt-4-125">Department of Surgery, Kansai Medical University, Hirakata, Japan</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Shoji, Tetsuji" sort="Shoji, Tetsuji" uniqKey="Shoji T" first="Tetsuji" last="Shoji">Tetsuji Shoji</name>
<affiliation><nlm:aff id="af3-bctt-4-125">Shoji Clinic, Osaka, Japan</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kuwana, Kayoko" sort="Kuwana, Kayoko" uniqKey="Kuwana K" first="Kayoko" last="Kuwana">Kayoko Kuwana</name>
<affiliation><nlm:aff id="af1-bctt-4-125">Department of Surgery, Kansai Medical University, Hirakata, Japan</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kwon, A Hon" sort="Kwon, A Hon" uniqKey="Kwon A" first="A-Hon" last="Kwon">A-Hon Kwon</name>
<affiliation><nlm:aff id="af1-bctt-4-125">Department of Surgery, Kansai Medical University, Hirakata, Japan</nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">Breast Cancer : Targets and Therapy</title>
<idno type="eISSN">1179-1314</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec><title>Background</title>
<p>Sentinel lymph node biopsy has steadily replaced axillary lymph node dissection (ALND) for staging clinically node-negative breast cancer. However, ALND remains standard management of the axilla when a tumor-positive sentinel lymph node is identified.</p>
</sec>
<sec><title>Methods</title>
<p>We identified 460 patients with breast cancer (clinically T1/T2N0M0) from the database for 1999–2004. Patient age ranged from 26 to 81 (median 50) years. Patients who underwent mastectomy or breast-conserving surgery with or without ALND were compared for regional recurrence, disease-free survival, and overall survival.</p>
</sec>
<sec><title>Results</title>
<p>Patients with ALND (n = 308) were compared with the no ALND group (n = 152). Five-year overall survival and disease-free survival were not significantly different between the two groups, while there was a significant difference between them for regional recurrence. Of the 152 patients who did not undergo axillary dissection, four developed ipsilateral axillary disease, most of whom were rescued by delayed axillary dissection. Further, the criterion for identifying lymphedema was used, ie, a 2 cm circumferential change at any measured location. As a result, the incidence of lymphedema in the ALND group was 12.7%, while it was not seen in the non ALND group.</p>
</sec>
<sec><title>Conclusion</title>
<p>There is a possibility that ALND may be omitted for cT1/T2N0M0 breast cancer through a combination of hormone therapy and adjuvant chemotherapy.</p>
</sec>
</div>
</front>
</TEI>
<pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">Breast Cancer (Dove Med Press)</journal-id>
<journal-id journal-id-type="iso-abbrev">Breast Cancer (Dove Med Press)</journal-id>
<journal-id journal-id-type="publisher-id">Breast Cancer: Targets and Therapy</journal-id>
<journal-title-group><journal-title>Breast Cancer : Targets and Therapy</journal-title>
</journal-title-group>
<issn pub-type="epub">1179-1314</issn>
<publisher><publisher-name>Dove Medical Press</publisher-name>
</publisher>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">24367200</article-id>
<article-id pub-id-type="pmc">3846707</article-id>
<article-id pub-id-type="doi">10.2147/BCTT.S36054</article-id>
<article-id pub-id-type="publisher-id">bctt-4-125</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject>
</subj-group>
</article-categories>
<title-group><article-title>Five-year follow-up of treatment outcomes in patients with early-stage breast cancer and clinically negative axillary nodes treated with no lymph node dissection or axillary clearance</article-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Yamamoto</surname>
<given-names>Daigo</given-names>
</name>
<xref ref-type="aff" rid="af1-bctt-4-125">1</xref>
<xref ref-type="corresp" rid="c1-bctt-4-125"></xref>
</contrib>
<contrib contrib-type="author"><name><surname>Tanaka</surname>
<given-names>Kanji</given-names>
</name>
<xref ref-type="aff" rid="af2-bctt-4-125">2</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Tsubota</surname>
<given-names>Yu</given-names>
</name>
<xref ref-type="aff" rid="af1-bctt-4-125">1</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Sueoka</surname>
<given-names>Noriko</given-names>
</name>
<xref ref-type="aff" rid="af1-bctt-4-125">1</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Shoji</surname>
<given-names>Tetsuji</given-names>
</name>
<xref ref-type="aff" rid="af3-bctt-4-125">3</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Kuwana</surname>
<given-names>Kayoko</given-names>
</name>
<xref ref-type="aff" rid="af1-bctt-4-125">1</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Kwon</surname>
<given-names>A-Hon</given-names>
</name>
<xref ref-type="aff" rid="af1-bctt-4-125">1</xref>
</contrib>
</contrib-group>
<aff id="af1-bctt-4-125"><label>1</label>
Department of Surgery, Kansai Medical University, Hirakata, Japan</aff>
<aff id="af2-bctt-4-125"><label>2</label>
Ribon-Rose Tanaka Kanji Breast Clinic, Japan</aff>
<aff id="af3-bctt-4-125"><label>3</label>
Shoji Clinic, Osaka, Japan</aff>
<author-notes><corresp id="c1-bctt-4-125">Correspondence: Daigo Yamamoto, Department of Surgery, Kansai Medical University, Hirakata, Osaka 570-8507, Japan, Tel +817 2804 0101, Fax +817 2804 0170, Email <email>yamamotd@hirakata.ac.jp</email>
</corresp>
</author-notes>
<pub-date pub-type="collection"><year>2012</year>
</pub-date>
<pub-date pub-type="epub"><day>27</day>
<month>8</month>
<year>2012</year>
</pub-date>
<volume>4</volume>
<fpage>125</fpage>
<lpage>129</lpage>
<permissions><copyright-statement>© 2012 Yamamoto et al, publisher and licensee Dove Medical Press Ltd</copyright-statement>
<copyright-year>2012</copyright-year>
<license><license-p>This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.</license-p>
</license>
</permissions>
<abstract><sec><title>Background</title>
<p>Sentinel lymph node biopsy has steadily replaced axillary lymph node dissection (ALND) for staging clinically node-negative breast cancer. However, ALND remains standard management of the axilla when a tumor-positive sentinel lymph node is identified.</p>
</sec>
<sec><title>Methods</title>
<p>We identified 460 patients with breast cancer (clinically T1/T2N0M0) from the database for 1999–2004. Patient age ranged from 26 to 81 (median 50) years. Patients who underwent mastectomy or breast-conserving surgery with or without ALND were compared for regional recurrence, disease-free survival, and overall survival.</p>
</sec>
<sec><title>Results</title>
<p>Patients with ALND (n = 308) were compared with the no ALND group (n = 152). Five-year overall survival and disease-free survival were not significantly different between the two groups, while there was a significant difference between them for regional recurrence. Of the 152 patients who did not undergo axillary dissection, four developed ipsilateral axillary disease, most of whom were rescued by delayed axillary dissection. Further, the criterion for identifying lymphedema was used, ie, a 2 cm circumferential change at any measured location. As a result, the incidence of lymphedema in the ALND group was 12.7%, while it was not seen in the non ALND group.</p>
</sec>
<sec><title>Conclusion</title>
<p>There is a possibility that ALND may be omitted for cT1/T2N0M0 breast cancer through a combination of hormone therapy and adjuvant chemotherapy.</p>
</sec>
</abstract>
<kwd-group><title>Keywords</title>
<kwd>breast cancer</kwd>
<kwd>axillary lymph node dissection</kwd>
</kwd-group>
</article-meta>
</front>
</pmc>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D01 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 002D01 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    Pmc
   |étape=   Corpus
   |type=    RBID
   |clé=     PMC:3846707
   |texte=   Five-year follow-up of treatment outcomes in patients with early-stage breast cancer and clinically negative axillary nodes treated with no lymph node dissection or axillary clearance
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i   -Sk "pubmed:24367200" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

Five-year follow-up of treatment outcomes in patients with early-stage breast cancer and clinically negative axillary nodes treated with no lymph node dissection or axillary clearance

Five-year follow-up of treatment outcomes in patients with early-stage breast cancer and clinically negative axillary nodes treated with no lymph node dissection or axillary clearance

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki